Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marisa Chau

Showing results (21-30 of 27) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 27 results.
BMJ Open|May 29, 2021
Exenatide once weekly over 2 years as a potential disease-modifying treatment for Parkinson's disease: protocol for a multicentre, randomised, double blind, parallel group, placebo controlled, phase 3 trial: The 'Exenatide-PD3' studyNirosen Vijiaratnam, Christine Girges, Grace Auld, et al.
International Journal of Stroke : Official Journal of the International Stroke Society|January 12, 2022
Optimal timing of anticoagulation after acute ischemic stroke with atrial fibrillation (OPTIMAS): Protocol for a randomized controlled trialJonathan G Best, Liz Arram, Norin Ahmed, et al.
Research and Practice in Thrombosis and Haemostasis|August 14, 2024
Rivaroxaban for stroke patients with antiphospholipid syndrome (RISAPS): protocol for a randomized controlled, phase IIb proof-of-principle trialPrabal Mittal, Rafael Gafoor, Zara Sayar, et al.
Lancet (London, England)|November 4, 2024
Optimal timing of anticoagulation after acute ischaemic stroke with atrial fibrillation (OPTIMAS): a multicentre, blinded-endpoint, phase 4, randomised controlled trialDavid J Werring, Hakim-Moulay Dehbi, Norin Ahmed, et al.
Stroke|April 1, 2026
Early Versus Delayed Anticoagulation in Acute Ischemic Stroke According to Atrial Fibrillation Subtype and Time of Diagnosis: Subgroup Analysis of the OPTIMAS Randomized Controlled TrialJames Lyon, Philip S Nash, Norin Ahmed, et al.
Stroke|May 22, 2025
Anticoagulation Timing in Acute Stroke With Atrial Fibrillation According to Chronic Kidney Disease: The OPTIMAS TrialPhilip S Nash, Hakim-Moulay Dehbi, Norin Ahmed, et al.
International Journal of Stroke : Official Journal of the International Stroke Society|March 30, 2026
Early Versus Delayed Anticoagulation in Acute Ischaemic Stroke with Atrial Fibrillation According to Infarct Volume and Location: a Prespecified Subgroup Analysis of the OPTIMAS Randomised Controlled TrialPhilip S Nash, Jonathan Best, James Lyon, et al.
Pageof 3

Showing results (21-30 of 27) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 27 results.
BMJ Open|May 29, 2021
Exenatide once weekly over 2 years as a potential disease-modifying treatment for Parkinson's disease: protocol for a multicentre, randomised, double blind, parallel group, placebo controlled, phase 3 trial: The 'Exenatide-PD3' studyNirosen Vijiaratnam, Christine Girges, Grace Auld, et al.
International Journal of Stroke : Official Journal of the International Stroke Society|January 12, 2022
Optimal timing of anticoagulation after acute ischemic stroke with atrial fibrillation (OPTIMAS): Protocol for a randomized controlled trialJonathan G Best, Liz Arram, Norin Ahmed, et al.
Research and Practice in Thrombosis and Haemostasis|August 14, 2024
Rivaroxaban for stroke patients with antiphospholipid syndrome (RISAPS): protocol for a randomized controlled, phase IIb proof-of-principle trialPrabal Mittal, Rafael Gafoor, Zara Sayar, et al.
Lancet (London, England)|November 4, 2024
Optimal timing of anticoagulation after acute ischaemic stroke with atrial fibrillation (OPTIMAS): a multicentre, blinded-endpoint, phase 4, randomised controlled trialDavid J Werring, Hakim-Moulay Dehbi, Norin Ahmed, et al.
Stroke|April 1, 2026
Early Versus Delayed Anticoagulation in Acute Ischemic Stroke According to Atrial Fibrillation Subtype and Time of Diagnosis: Subgroup Analysis of the OPTIMAS Randomized Controlled TrialJames Lyon, Philip S Nash, Norin Ahmed, et al.
Stroke|May 22, 2025
Anticoagulation Timing in Acute Stroke With Atrial Fibrillation According to Chronic Kidney Disease: The OPTIMAS TrialPhilip S Nash, Hakim-Moulay Dehbi, Norin Ahmed, et al.
International Journal of Stroke : Official Journal of the International Stroke Society|March 30, 2026
Early Versus Delayed Anticoagulation in Acute Ischaemic Stroke with Atrial Fibrillation According to Infarct Volume and Location: a Prespecified Subgroup Analysis of the OPTIMAS Randomised Controlled TrialPhilip S Nash, Jonathan Best, James Lyon, et al.
Pageof 3